Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Drugs Used in Upper Respiratory Disorders: Overview

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...

Microbiome of the Eye

Microbiome of the Eye

The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Drug Delivery: Miscellaneous Routes

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Unraveling the immune-microbial axis in chronic ocular surface disease.

Current opinion in allergy and clinical immunology·2025

Same author

Bridging diagnostic gaps in anterior ocular inflammatory surface diseases.

Current opinion in allergy and clinical immunology·2025

Same author

From innovation to implementation: strengthening anterior ocular inflammatory surface diseases diagnostics through global health policy.

Current opinion in allergy and clinical immunology·2025

Same author

The Link Between Allergic Rhinitis and Keratoconus: A Call for Greater Awareness, Early Intervention, and Future Ocular Surface Diagnostic Tools.

The journal of allergy and clinical immunology. In practice·2024

Same author

The collaborative medical practice of the ocular surface: a major role of the allergist/immunologist.

Current opinion in allergy and clinical immunology·2024

Same author

Ocular surface disorders: office procedures for the allergist/clinical immunologist.

Current opinion in allergy and clinical immunology·2024

Search research articles

Related Experiment Video

Updated: Jun 20, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Emerging drugs for conjunctivitis.

Catherine Origlieri¹, Leonard Bielory

¹STARx Allergy & Asthma Center, UMDNJ - New Jersey Medical School, 400 Mountain Avenue, Springfield, New Jersey, NJ 07081, USA.

Expert Opinion on Emerging Drugs

|August 28, 2009

Summary

New ophthalmic agents are in development to treat conjunctivitis, offering improved outcomes for both infectious and noninfectious forms. These promising therapies aim to overcome the limitations of current conjunctivitis treatments.

Area of Science:

Ophthalmology
Pharmacology

Background:

Conjunctivitis is a common eye condition that can lead to visual impairment.
Causes include infections (bacterial, viral, fungal, parasitic) and noninfectious triggers (allergies, dry eye, chemical exposure).
Current treatments often require frequent application and may not be fully effective.

Purpose of the Study:

To review emerging conjunctivitis therapies in clinical development.
To compare novel treatments with existing options for conjunctivitis management.

Main Methods:

Searched the Pharmaprojects database for global conjunctivitis drug development.
Reviewed current treatment guidelines for infectious and noninfectious conjunctivitis using PubMed and Ovid.

Main Results:

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Conjunctival Commensal Isolation and Identification in Mice

Conjunctival Commensal Isolation and Identification in Mice

Published on: May 1, 2021

Related Experiment Videos

Last Updated: Jun 20, 2026

Intracameral Injection in Rats with Low Risk of Adverse Effects

Intracameral Injection in Rats with Low Risk of Adverse Effects

Published on: May 31, 2024

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Conjunctival Commensal Isolation and Identification in Mice

Conjunctival Commensal Isolation and Identification in Mice

Published on: May 1, 2021

Several new compounds are under investigation, including antimicrobials, antihistamines, anti-inflammatories, immunomodulators, and a thiazolidinedione.
These agents demonstrate potential for enhanced clinical outcomes in conjunctivitis.

Conclusions:

Novel therapeutic agents show promise for improving the management of conjunctivitis.
Future directions in conjunctivitis treatment include these advanced pharmacological options.